Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
Fiction
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/f4/5f/99/f45f99fe-91c0-52ba-3ef3-5af3bd10ce93/mza_13514259117033196619.jpg/600x600bb.jpg
Skin and Joints Podcast
Mimi Tran, Aaron Sihota, Danny Mansour, Ashley Yip, Julia Tan, Touraj Khosravi, Anastasiya Muntyanu
68 episodes
18 hours ago
A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.
Show more...
Medicine
Health & Fitness,
Science,
Life Sciences
RSS
All content for Skin and Joints Podcast is the property of Mimi Tran, Aaron Sihota, Danny Mansour, Ashley Yip, Julia Tan, Touraj Khosravi, Anastasiya Muntyanu and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.
Show more...
Medicine
Health & Fitness,
Science,
Life Sciences
https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/49fa8aef-f7ec-4671-a1f7-14878d5707d9/3000x3000/newpfi2.jpg?aid=rss_feed
PART 1: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo
Skin and Joints Podcast
28 minutes 14 seconds
7 months ago
PART 1: What's New in Atopic Dermatitis at AAD 2025 with Dr. Wei Jing Loo
🎙️PART 1: From Dupilumab to Abrocitinib🩺✨ Sun-kissed Orlando sets the stage as we talk all things eczema from dupilumab to abrocitinib—after squeezing in a little Disney magic, of course. Listen to fresh poster data on switching stubborn AD patients from dupilumab to abrocitinib and debate whether to hit hard with 200 mg or start slow at 100 mg. Rapid EASI-90 gains, itch-free nights, and a “flat-line” durability curve you’ll actually love? Along the way you’ll hear: The secret sauce for counseling risk-averse AD patients who’ve already weathered methotrexate and cyclosporine. Why comorbid alopecia or vitiligo might tip you toward a JAK-first strategy. 🎯 Learning Objectives Identify the clinical profile of AD patients who fail or can’t tolerate dupilumab and may benefit from switching to a JAK inhibitor. Compare real-world efficacy & speed of response between abrocitinib 100 mg vs 200 mg, and craft pragmatic dose-titration plans. Integrate patient-reported outcomes (itch, DLQI) and comorbidity considerations into shared decision-making for advanced AD therapy. #SkinAndJointsPodcast #AAD2025 #AtopicDermatitis #EczemaCare #JAKinhibitors #Dupilumab #Abrocitinib #DermTwitter #MedEd #Podcast 🎧 About Dr Wei Jing Loo, BSc (Med), MBBS, MRCP (UK), FRCP(c) Dermatologist  | London, ON Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals 📻www.skinandjoints.ca
Skin and Joints Podcast
A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.